Not Losing Momentum: Cross-Sectional Insights into Ibogaine Clinical Trials
AI-extracted · unverified · confirm at source
Cross-sectional analysis of 9 ibogaine/noribogaine clinical trials from global registries. Documents methodological heterogeneity, early-phase dominance, and variable cardiac safety protocols. Calls for standardised framework.
Dosing: Ibogaine: 20–600 mg fixed or 3–15 mg/kg weight-based; Noribogaine: 3–180 mg (across 9 trials) (oral)
Safety data present: QTC
Contraindications: Pre-existing cardiovascular disease or prolonged QT interval (exclusion criterion across multiple trials), Major psychiatric disorders excluding target SUD (common exclusion), Recent illicit drug use (variable washout periods across trials), Concurrent methadone use without stable dosing (trial-specific), Abnormal baseline ECG findings (QTcF >450 ms in NCT06480981)